ArticlePloS one2025
Pain, fatigue, and associated gene expressions over chemotherapy in patients with colorectal cancer.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal Associations Between Inflammatory Biomarkers and Fatigue in Patients With Colorectal Cancer: A Multicenter Study.Cancer medicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPatients with colorectal cancer undergoing chemotherapy often experience significant pain and fatigue. Limitations in understanding the complex phenotypes and biological mechanisms of these symptoms hinder effective interventions.
objectivesThis study aimed to identify the pain and fatigue patterns during one chemotherapy cycle and associated gene expression profiles.
methodIn a prospective longitudinal study, 34 patients with colorectal cancer from a major cancer center in the Northeastern US were recruited. Self-reported outcome measures of pain and fatigue and blood samples were collected at baseline, post-chemotherapy, and at the end of the chemotherapy cycle. RNA sequencing followed by differential expression analysis identified changes in gene expression. Linear mixed models examined associations between symptoms and possible biomarkers over time.
resultsThe sample had a mean age of 58.4 years old, with 97% being white and non-Hispanic. Among participants, 44.1% had stage III cancer, and 26.5% were undergoing initial chemotherapy. Abdominal pain was the most frequently reported symptom. Fatigue levels significantly worsened post-chemotherapy (P = 0.011) and after recovery (P = 0.018). Critical pathways involved inflammatory response and myeloid cell development (FDR < 5%). Mixed-effect linear regression analysis revealed statistically significant associations between the upregulation of LILRA6 and higher pain interference (β = -6.621, p = 0.010) and fatigue (β = -6.621, p = 0.010), as well as between the downregulation of CACNG6 (β = -1.043, p = 0.047) and PRSS33 upregulation (β = 1.384, p = 0.038) and increased pain interference. Given the small sample size, these findings should be interpreted with caution.
conclusionThese findings suggest inflammation and specific biomarkers may drive pain and fatigue during chemotherapy. Further preclinical models or clinical cohorts are needed to validate these results and explore potential implications for targeted interventions to reduce symptom burden in patients with colorectal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.